• category:Pipeline
HanAll Biopharma kicks off phase 3 DED trial on topical anti-inflammatory
Pipeline

HanAll Biopharma kicks off phase 3 DED trial on topical anti-inflammatory

VELOS-4 trial is evaluating tanfanerept for improvement in Schirmer test following last year’s phase 3 primary endpoint miss.
 EyePoint fails to meet primary goal in phase 2 NPDR trial
Pipeline

EyePoint fails to meet primary goal in phase 2 NPDR trial

Interim 9-month data finds DURAVYU demonstrated a continued favorable safety profile and tolerability similar to its other indications for DME and wet AMD.
Cell therapy dosing concludes for Emmecell's corneal edema trial
Pipeline

Cell therapy dosing concludes for Emmecell's corneal edema trial

Minimally-invasive cell therapy has been designed to repopulate dysfunctional corneal endothelial cells, potentially eliminating the need for transplantation.
FDA accepts Eluminex's IND for DME trispecific fusion antibody
Pipeline

FDA accepts Eluminex's IND for DME trispecific fusion antibody

Protein therapeutic is formulated for intravitreal injection and targets key angiogenesis pathways: VEGF-A, VEGF-B, placental growth factor, Ang-2, and IL-6R.
Qlaris Bio raises $24M in financing for IOP-lowering glaucoma candidate
Pipeline

Qlaris Bio raises $24M in financing for IOP-lowering glaucoma candidate

Latest funding supports ongoing clinical development of IOP-lowering therapeutic formulated to reduce episcleral venous pressure.
Naegis Pharma secures financing to advance retinal disease candidate
Pipeline

Naegis Pharma secures financing to advance retinal disease candidate

Funding will support IND-application for phase 2 trial on investigational asset, which is designed to protect the retina and cornea from damage via oral administration.
RevOpsis raises $16.5M to advance nAMD tri-specific therapy
Pipeline

RevOpsis raises $16.5M to advance nAMD tri-specific therapy

Seed funding will support IND-enabling clinical studies on the first monotherapy agent to target all three angiogenic pathways.
SalioGen Therapeutics's gene coding therapy targets Stargardt disease
Pipeline

SalioGen Therapeutics's gene coding therapy targets Stargardt disease

One-time, non-viral subretinal injection uses novel Gene Coding technology for gene integration.
Ocuphire enrolls first patient in LYNX-2 phase 3 study for phentolamine
Pipeline

Ocuphire enrolls first patient in LYNX-2 phase 3 study for phentolamine

Trial is evaluating phentolamine ophthalmic solution 0.75% (PS) for decreased VA under low (mesopic) light conditions after keratorefractive surgery.
Pantheon Vision closes on $1.8M to advance bioengineered corneal implants
Pipeline

Pantheon Vision closes on $1.8M to advance bioengineered corneal implants

Company’s total funding adds up to over $4 million as it seeks to eliminate corneal blindness by reducing the global reliance on donated corneal tissues.
Kiora Pharma secures IRD grant for late-stage RP trial
Pipeline

Kiora Pharma secures IRD grant for late-stage RP trial

Funding from the Choroideremia Research Foundation will support testing validation in the ABACUS-2 phase 2 trial on KIO-301, a molecular photoswitch.
Oculis releases positive phase 3 data from OPTIMIZE-1 trial for post-op inflammation and pain
Pipeline

Oculis releases positive phase 3 data from OPTIMIZE-1 trial for post-op inflammation and pain

Announced at ASCRS, favorable results on once-daily, topical, and preservative-free topical formulation may support an eventual NDA submission.
LENZ Therapeutics reports positive phase 3 data for presbyopia eye drops
Pipeline

LENZ Therapeutics reports positive phase 3 data for presbyopia eye drops

CLARITY 1 and 2 trials report statistically significant topline data for single-use, once-daily, and preservative-free LNZ100.  
Ocugen's IND amendment gets FDA OK for phase 3 RP gene therapy trial
Pipeline

Ocugen's IND amendment gets FDA OK for phase 3 RP gene therapy trial

Investigational candidate OCU400 is the first potential treatment for RP associated with rhodopsin mutations.
Travoprost implant shows robust IOP-lowering in phase 3 study
Pipeline

Travoprost implant shows robust IOP-lowering in phase 3 study

Phase 3 trial finds travoprost implant as safe and effective alternative to topical IOP-lowering meds.
Aurion doses first Canadian patient in allogeneic cell therapy trial for CED
Pipeline

Aurion doses first Canadian patient in allogeneic cell therapy trial for CED

Corneal endothelial dysfunction candidate is being studied across clinical sites in North America.
Aldeyra to resubmit NDA for reproxalap DED treatment
Pipeline

Aldeyra to resubmit NDA for reproxalap DED treatment

Company plans to initiate a dry eye chamber trial four months after the FDA voiced concerns over the candidate’s clinical efficacy.
Nicox reports favorable IOP lowering for OAG in phase 3 eye drop trial
Pipeline

Nicox reports favorable IOP lowering for OAG in phase 3 eye drop trial

Latest data from Mont Blanc study finds the NO-bimatoprost combo formulation surpasses latanoprost at all time points.
REGENXBIO shares 2-year data on gene therapy injection for wet AMD
Pipeline

REGENXBIO shares 2-year data on gene therapy injection for wet AMD

Dose-escalation study reports stable or improved vision and retinal anatomy up to 2 years.
Nanoscope reports positive data from RESTORE trial on optogenetic therapy for RP
Pipeline

Nanoscope reports positive data from RESTORE trial on optogenetic therapy for RP

Statistical significance noted for MCO-010 in demonstrating clinically meaningful vision improvement for legally blind, advanced RP patients.